Michael King - SAB Biotherapeutics EVP CFO
| SABSW Stock | USD 0.03 0 4.65% |
CFO
Michael King is EVP CFO of SAB Biotherapeutics
| Age | 63 |
| Address | 777 W 41st St., Miami Beach, FL, United States, 33140 |
| Phone | 605 679 6980 |
| Web | https://www.sabbiotherapeutics.com |
Michael King Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael King against SAB Biotherapeutics stock is an integral part of due diligence when investing in SAB Biotherapeutics. Michael King insider activity provides valuable insight into whether SAB Biotherapeutics is net buyers or sellers over its current business cycle. Note, SAB Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell SAB Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael King over a year ago Disposition of 27371 shares by Michael King of Pactiv Evergreen at 13.23 subject to Rule 16b-3 | ||
Michael King over a year ago Payment of 49335 shares by Michael King of Pactiv Evergreen subject to Rule 16b-3 |
SAB Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.788) % which means that it has lost $0.788 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7473) %, meaning that it generated substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.55 in 2025. Return On Capital Employed is likely to drop to -0.63 in 2025. At this time, SAB Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 327.2 K in 2025, whereas Total Assets are likely to drop slightly above 63.5 M in 2025.Similar Executives
| Found 3 records | CFO Age | ||
| Herbert Cross | Jasper Therapeutics | 52 | |
| Herbert CPA | Jasper Therapeutics | 53 | |
| Lucy To | SAB Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 |
SAB Biotherapeutics Leadership Team
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Executive Officer | ||
| Mark Conley, Interim Officer | ||
| Eddie Sullivan, President CoFounder | ||
| Carlos Carillo, Senior Affairs | ||
| Lucy To, EVP CFO | ||
| Christoph MBA, Executive COO | ||
| Michael King, EVP CFO | ||
| Samuel Reich, Executive Chairman | ||
| Christine MBA, CoFounder Director | ||
| Edward DVM, CoFounder Observer |
SAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SAB Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Number Of Shares Shorted | 1.18 K | ||||
| Price To Earning | 0.21 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (25.38 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Total Debt | 5.91 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.